We plan to continue to advance the "SWARM-P.a." Antibiotic use is often associated with toxicities (e.g. kidneys, bone marrow, hearing). We no longer offer AP-SA01 through any expanded access program. Feasibility batches of AP-SA02 have been completed meeting all intended specifications. Competition The development and commercialization of new drugs is highly competitive. Any agency or judicial enforcement action could have a material adverse effect on us. Clinical trials must be conducted in accordance with GCP requirements. We intend to request Fast Track designation for our product candidates if applicable. After a BLA is approved, the product also may be subject to official lot release. The maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops. Orphan drug designation must be requested before submitting a MAA. The requirements governing drug pricing vary widely from country to country. We will need to raise additional capital to support our operations. As of December 31, 2020, we had cash and cash equivalents of $9.6 million. Patent term extensions may not be available for these patents. Moreover, any such event could delay the development of our product candidates.